Patient demographics and response to alemtuzumab therapy
. | No. patients (%) . |
|---|---|
| Demographics | |
| Male sex | 29 (81) |
| Fludarabine refractory | 29 (81) |
| Rai stage III/IV | 27 (75) |
| del(17p13.1) | 12 (33) |
| Response | |
| Complete | 2 (6) |
| Partial | 9 (25) |
| None | 27 (75) |
. | No. patients (%) . |
|---|---|
| Demographics | |
| Male sex | 29 (81) |
| Fludarabine refractory | 29 (81) |
| Rai stage III/IV | 27 (75) |
| del(17p13.1) | 12 (33) |
| Response | |
| Complete | 2 (6) |
| Partial | 9 (25) |
| None | 27 (75) |
Median age of patients was 61 years (range, 42-74 years). Median number of previous therapies was 3 (range, 1-12). Median duration of response was 9.5 months (range, 3-36 months).